Direct medical cost of pelvic inflammatory disease and its sequelae: Decreasing, but still substantial

被引:135
作者
Rein, DB
Kassler, WJ
Irwin, KL
Rabiee, L
机构
[1] Ctr Dis Control & Prevent, Natl Ctr HIV Sexually Transmitted Dis & TB Preven, Div STD Prevent, Hlth Serv Res & Evaluat Branch, Atlanta, GA 30333 USA
[2] Georgia State Univ, Georgia Inst Technol, Joint PhD Program Publ Policy, Atlanta, GA 30303 USA
[3] New Hampshire Dept Hlth & Human Serv, Concord, NH 03301 USA
关键词
D O I
10.1016/S0029-7844(99)00551-7
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To estimate direct medical costs and average lifetime cost per case of pelvic inflammatory disease (PID). Methods: We estimated the direct medical expenditures for PID and its three major sequelae (chronic pelvic pain, ectopic pregnancy, and infertility) and determined the average lifetime cost of a case of PID and its sequelae. We analyzed 3 years of claims data of privately insured individuals to determine costs, and 3 years of national survey data to determine number of cases of PID, chronic pelvic pain, and ectopic pregnancy. We developed a probability model to determine the-average lifetime cost of a case of PID. Results: Direct medical expenditures for PID and its sequelae were estimated at $1.88 billion in 1998: $1.06 billion for PID, $166 million for chronic pelvic pain, $295 million for ectopic pregnancy, and $360 million for infertility associated with PID. The expected lifetime cost of a case of PID was $1167 in 1998 dollars. The majority of those costs ($843 per case) represent care for acute PID rather than diagnosis and treatment of sequelae. Approximately 73% of cases will not accrue costs beyond the treatment of acute PID. Conclusion: The direct medical cost of PID is still substantial. The majority of PID related costs are incurred in the treatment of acute PID. Because most PID-related costs arise in the first year from treatment of acute PID infection, strategies that prevent PID are likely to be cost-effective within a: single year. (Obstet Gynecol 2000;95:397-402, (C) 2000 by The American College of Obstetricians and Gynecologists.).
引用
收藏
页码:397 / 402
页数:6
相关论文
共 25 条
[1]  
*AM MED ASS, 1996, ICD9CM AM MED ASS
[2]  
*AM SOC HLTH ASS, 1995, STD COUNS TREATM GUI, P209
[3]  
[Anonymous], 1995, MMWR Recomm Rep, V44, P1
[4]  
[Anonymous], [No title captured]
[5]  
[Anonymous], 1997, PHYS DESK REF, P1723
[6]  
Centers for Disease Control and Prevention, 1998, MMWR-MORBID MORTAL W, V47, P79
[7]   ECONOMIC CONSEQUENCES OF PELVIC INFLAMMATORY DISEASE IN THE UNITED-STATES [J].
CURRAN, JW .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1980, 138 (07) :848-851
[8]   THE COST-EFFECTIVENESS OF AZITHROMYCIN FOR CHLAMYDIA-TRACHOMATIS INFECTIONS IN WOMEN [J].
HADDIX, AC ;
HILLIS, SD ;
KASSLER, WJ .
SEXUALLY TRANSMITTED DISEASES, 1995, 22 (05) :274-280
[9]   NEW OPPORTUNITIES FOR CHLAMYDIA PREVENTION - APPLICATIONS OF SCIENCE TO PUBLIC-HEALTH PRACTICE [J].
HILLIS, S ;
BLACK, C ;
NEWHALL, J ;
WALSH, C ;
GROSECLOSE, SL .
SEXUALLY TRANSMITTED DISEASES, 1995, 22 (03) :197-202
[10]   Public health departments providing sexually transmitted disease services [J].
Landry, DJ ;
Forrest, JD .
FAMILY PLANNING PERSPECTIVES, 1996, 28 (06) :261-266